drugset
drugset / Trial / NCT05430217

Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo

NCT05430217 ↗

Phase 3 Completed 268 enrolled Valenta Pharm JSC
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to evaluate the efficacy and safety of Buspirone, sustained-release tablets, 15 mg in patients with autonomic dysfunction syndrome accompanied by vertigo

Timeline

Start
2022-01-28
Primary completion
2022-05-09
Completion
2022-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Buspirone Small molecule 15 mg —

Indications

dysautonomia